美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Defiance Daily Target 2X Long MRNA ETF

103.09

+23.1428.94%

盤後：101.70-1.3900-1.35%19:59 EDT

成交量：101.47萬

成交額：9,934.26萬

市值：3,092.70萬

市盈率：- -

高：105.71

開：85.01

低：82.51

收：79.95

52周最高：143.84

52周最低：14.95

股本：30.00萬

流通股本：30.00萬

量比：0.68

換手率：338.25%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

Moderna國際新冠疫苗銷售超預期一季度業績亮眼

Moderna高管稱公司正等待FDA指導以恢復流感-新冠聯合疫苗美國申報流程

Moderna高管稱中東持續衝突對2026年業績展望無實質影響——電話會議透露

Moderna公布第一季度每股虧損3.40美元

Moderna預計2026年恢復銷售增長將獲多項新批准含季節性流感疫苗

賽富時推出互聯平台，整合多區域商業用户的數據、人工智能與客户互動

Moderna啓動mRNA-1018三期臨床試驗美英首批受試者完成接種

Moderna獲歐盟批准上市Mcombriax——全球首款mRNA流感與新冠聯合疫苗

OpenAI攜手安進、Moderna等業界巨頭全面部署Gpt-Rosalind人工智能工作流解決方案

Moderna將於2026年7月8日前向Arbutus/Genevant支付9.5億美元無條件一次性款項

ETF日報｜三倍做多半導體ETF漲近6%；納指三倍做多ETF升逾4%；加密與半導體產品相對跑贏

老虎资讯综合

Moderna股價盤前飆升3.7% 公司同意支付高達22.5億美元和解新冠疫苗專利糾紛

Moderna預計2026年恢復營收增長，年末流動性超50億美元，2028年實現盈虧平衡

Roivant Sciences子公司Genevant將向Moderna授予傳染病應用LNP遞送技術非獨家許可

Moderna預計2026年第一季度將因和解支付計入9.5億美元費用

Moderna最新預測：2026年末現金及現金等價物預計達45-50億美元區間

Moderna宣佈新冠流感聯合疫苗Mcombriax或於2026/2027季登陸部分歐盟市場

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/stock/MRNX/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MRNX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MRNX\",,,,,undefined,":{"symbol":"MRNX","market":"US","secType":"STK","nameCN":"Defiance Daily Target 2X Long MRNA ETF","latestPrice":103.09,"timestamp":1787688000000,"preClose":79.95,"halted":0,"volume":1014744,"hourTrading":{"tag":"盘后","latestPrice":101.7,"preClose":103.09,"latestTime":"19:59 EDT","volume":23992,"amount":2456158.7007,"timestamp":1787702344344,"change":-1.39,"changeRate":-0.013483,"amplitude":0.016199},"delay":0,"changeRate":0.2894308943089431,"floatShares":300000,"shares":300000,"eps":0,"marketStatus":"已收盤","change":23.14,"latestTime":"08-25 16:00:00 EDT","open":85.01,"high":105.71,"low":82.512,"amount":99342625.80479999,"amplitude":0.290156,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1787731200000},"marketStatusCode":5,"adr":0,"exchange":"ARCA","adjPreClose":79.95,"sharesOutstanding":30000,"nav":80.08,"aum":24824800,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":85.58,"preClose":79.95,"latestTime":"09:28 EDT","volume":6477,"amount":544744.06926,"timestamp":1787664533763,"change":5.63,"changeRate":0.070419,"amplitude":0.066917},"postHourTrading":{"tag":"盘后","latestPrice":101.7,"preClose":103.09,"latestTime":"19:59 EDT","volume":23992,"amount":2456158.7007,"timestamp":1787702344344,"change":-1.39,"changeRate":-0.013483,"amplitude":0.016199},"volumeRatio":0.678916},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MRNX\",,,,,undefined,":{"symbol":"MRNX","floatShares":300000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.678916,"shares":300000,"dividePrice":0,"high":105.71,"amplitude":0.290156,"preClose":79.95,"low":82.512,"week52Low":14.95,"pbRate":"--","week52High":143.84,"institutionHeld":0,"latestPrice":103.09,"eps":0,"divideRate":0,"volume":1014744,"delay":0,"ttmEps":0,"open":85.01,"prevYearClose":20.61,"prevWeekClose":87.53,"prevMonthClose":24.27,"prevQuarterClose":42.65,"fiveDayClose":31.33,"twentyDayClose":25.355,"sixtyDayClose":21.0089},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MRNX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MRNX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MRNX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MRNX\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1151344645","title":"Moderna國際新冠疫苗銷售超預期 一季度業績亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=1151344645","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151344645?lang=zh_tw&edition=fundamental","pubTime":"2026-05-01 22:26","pubTimestamp":1777645603,"startTime":"0","endTime":"0","summary":"得益于长期政府合作框架下的国际新冠疫苗销售，Moderna第一季度营收实现逾三倍增长，达到3.89亿美元。\n这家位于马萨诸塞州剑桥的生物技术公司公布，三月季度净亏损13亿美元。若剔除与新冠疫苗技术诉讼和解相关的约9亿美元支出，经调整后亏损收窄至4.65亿美元，这一表现优于分析师预期。\n股价在盘前交易中曾强势上扬，但开盘后小幅走低。\nModerna正等待美国食品药品监督管理局于八月初对其首款独立流感疫苗的审批结果。此外，针对黑色素瘤的个性化癌症疫苗三期临床试验数据预计将于今年晚些公布，该疗法有望开创疾病治疗新路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4568","BK4533","MRNA","BK4551","BK4534","MRNY","MRNX","BK4501","BK4588","BK4139","BK4532","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150823990","title":"Moderna高管稱公司正等待FDA指導 以恢復流感-新冠聯合疫苗美國申報流程","url":"https://stock-news.laohu8.com/highlight/detail?id=1150823990","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150823990?lang=zh_tw&edition=fundamental","pubTime":"2026-05-01 20:24","pubTimestamp":1777638268,"startTime":"0","endTime":"0","summary":"Moderna公司高管近日表示，该公司正在等待美国食品药品监督管理局的进一步指导，以确定恢复流感与新冠联合疫苗在美国申报的后续步骤。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4534","BK4501","BK4533","BK4551","MRNY","BK4139","MRNA","BK4548","BK4568","BK4532","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192429043","title":"Moderna高管稱中東持續衝突對2026年業績展望無實質影響——電話會議透露","url":"https://stock-news.laohu8.com/highlight/detail?id=1192429043","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192429043?lang=zh_tw&edition=fundamental","pubTime":"2026-05-01 20:14","pubTimestamp":1777637655,"startTime":"0","endTime":"0","summary":"Moderna公司高管在最新电话会议中明确表示，目前中东地区的持续冲突不会对该公司截至2026年的业绩展望产生实质性影响。\n尽管地缘政治局势存在不确定性，但这家生物技术巨头对其中长期发展轨迹保持信心。公司方面强调，其全球业务布局和供应链韧性能够有效抵御区域性风险冲击。\n此次表态缓解了投资者对地缘政治因素可能影响疫苗巨头业绩的担忧。Moderna维持此前制定的2026年战略目标不变，包括研发管线推进和商业化拓展计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","MRNA","BK4548","BK4568","MRNX","BK4139","MRNY","BK4534","BK4533","BK4551","BK4585","BK4501","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104357139","title":"Moderna公布第一季度每股虧損3.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1104357139","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104357139?lang=zh_tw&edition=fundamental","pubTime":"2026-05-01 18:54","pubTimestamp":1777632878,"startTime":"0","endTime":"0","summary":"Moderna公司最新财报显示，第一季度营收达到3.89亿美元，远超华尔街分析师预期的2.28亿美元。尽管营收表现亮眼，公司当季每股亏损为3.40美元，略好于市场预估的每股亏损3.96美元。展望未来，Moderna预计将在2026年恢复销售增长态势，并有望获得包括季节性流感疫苗在内的多项新批准。财务储备方面，Moderna预计到2026年底，现金及投资规模将保持在45亿至50亿美元区间，为后续研发和市场拓展提供有力支撑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNY","BK4532","BK4139","BK4551","BK4533","MRNX","BK4501","BK4585","BK4588","MRNA","BK4568","BK4548","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131327497","title":"Moderna預計2026年恢復銷售增長 將獲多項新批准含季節性流感疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=1131327497","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131327497?lang=zh_tw&edition=fundamental","pubTime":"2026-05-01 18:31","pubTimestamp":1777631481,"startTime":"0","endTime":"0","summary":"生物技术公司Moderna, Inc.近日宣布，公司预计将在2026年重返销售增长轨道。这一乐观预测基于其研发管线中多个候选药物即将获得的监管批准，其中包括备受关注的季节性流感疫苗。\nModerna管理层表示，除了流感疫苗外，公司还预期在2026年前获得其他几项重要产品的上市许可。这些新产品的陆续获批将为公司注入新的增长动力，帮助其扭转近期销售额下滑的局面。\n该公司强调，其在mRNA技术平台的持续投入正在进入收获期，未来将通过多元化产品组合推动业绩回升。市场分析师认为，若这些预期顺利实现，Moderna有望重新确立其在疫苗领域的领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","BK4568","BK4501","BK4588","MRNA","BK4551","BK4548","BK4533","BK4139","MRNY","BK4585","BK4532","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137525165","title":"賽富時推出互聯平台，整合多區域商業用户的數據、人工智能與客户互動","url":"https://stock-news.laohu8.com/highlight/detail?id=1137525165","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137525165?lang=zh_tw&edition=fundamental","pubTime":"2026-04-28 21:08","pubTimestamp":1777381710,"startTime":"0","endTime":"0","summary":"赛富时宣布，其全新互联平台将实现跨多个地区的商业用户在数据管理、人工智能应用以及客户互动方面的无缝整合。该平台旨在通过统一的技术架构，帮助企业更高效地利用数据资源、部署智能算法，并优化客户参与流程，从而提升整体运营效能与市场响应速度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4538","LU1201861249.SGD","LU0792757196.USD","IE00B19Z9505.USD","LU0198837287.USD","LU0081259029.USD","BK4139","LU2265009873.SGD","LU0124676726.USD","LU0689626769.HKD","BK4568","LU0719512351.SGD","LU2756315318.SGD","LU0251131958.USD","LU2756315664.SGD","BK4551","IE00BQXX3F31.USD","IE00B19Z8X17.USD","LU1496350171.SGD","LU1235294995.USD","LU1496350502.SGD","LU0267386448.USD","LU0109392836.USD","LU0310799852.SGD","BK4581","LU0980610538.SGD","LU2357305700.SGD","BK4608","LU1201861165.SGD","LU0130518102.USD","LU0353189763.USD","LU0820561818.USD","BK4535","BK4527","LU0820561909.HKD","IE00BKVL7J92.USD","BK4567","LU0354030511.USD","LU2264538146.SGD","IE00BJTD4N35.SGD","LU0234572021.USD","LU0354030438.USD","LU0648001328.SGD","LU1720051108.HKD","LU1551013425.SGD","LU0353189680.USD","LU0048573561.USD","BK4505","LU2236285917.USD","LU0251142724.SGD","CRMG","LU1046421795.USD","BK4023","LU0472753341.HKD","BK4532","LU1791710400.SGD","MRNY","LU2361045086.USD","LU0130102774.USD","LU2361044865.SGD","BK4548","BK4613","LU0211328371.USD","BK4543","LU1989764748.USD","LU1803068979.SGD","LU0943347566.SGD","LU0211327993.USD","BK4561","LU1366333091.USD","BK4588","LU0234570918.USD","LU0477156953.USD","IE00BZ1G4Q59.USD","LU0069063385.USD","LU1989764664.SGD","LU2247934214.USD","LU2461242641.AUD","BK4607","BK4550","IE00BJTD4V19.USD","LU1951198990.SGD","BK4528","MRNX","LU0082616367.USD","LU1988902786.USD","LU0477156797.USD","LU0742534661.SGD","BK4579","LU1267930813.SGD","IE00BQXX3D17.EUR","LU0006306889.USD","BK4534","LU0511384066.AUD","LU0187121727.USD","LU1791710582.SGD","BK4585","LU1814569148.SGD","LU2361044949.HKD","LU0289961442.SGD","CRM","LU2244417387.USD","LU0648000940.SGD","LU0557290698.USD","LU0528227936.USD","BK4598","LU0820562030.AUD","BK4501","LU1551013342.USD","IE00B19Z8W00.USD","LU0127658192.USD","LU0689472784.USD","LU1267930490.SGD","LU0238689110.USD","LU1951200564.SGD","LU1064131342.USD","LU0106261372.USD","LU0157215616.USD","LU0889566641.SGD","IE00BQXX3C00.GBP","LU2458330243.SGD","LU0889565833.HKD","LU0057025933.USD","LU1316542783.SGD","LU1804176565.USD","LU1923623000.USD","LU2286300806.USD","LU0289739343.SGD","LU2087625088.SGD","LU1548497426.USD","LU1823568750.SGD","LU0642271901.SGD","LU0130517989.USD","LU0130103400.USD","LU2458330169.SGD","LU1720051017.SGD","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165083691","title":"Moderna啓動mRNA-1018三期臨床試驗 美英首批受試者完成接種","url":"https://stock-news.laohu8.com/highlight/detail?id=1165083691","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165083691?lang=zh_tw&edition=fundamental","pubTime":"2026-04-22 07:02","pubTimestamp":1776812535,"startTime":"0","endTime":"0","summary":"生物技术公司Moderna宣布，其针对H5型禽流感大流行的mRNA候选疫苗mRNA-1018已在美国和英国启动三期临床试验。该研究首批受试者近日完成首次接种，标志着这款基于信使核酸技术的创新型疫苗正式进入后期临床验证阶段。作为全球首款进入三期临床试验的mRNA基H5大流行流感疫苗，mRNA-1018采用与Moderna新冠疫苗相同的核心平台技术。若临床试验结果理想，mRNA-1018有望成为防范H5N1等高致病性禽流感病毒的重要武器，进一步完善全球大流行防范体系。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4501","BK4585","BK4548","BK4534","MRNY","MRNX","BK4532","BK4551","BK4139","MRNA","BK4588","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146538586","title":"Moderna獲歐盟批准上市Mcombriax——全球首款mRNA流感與新冠聯合疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=1146538586","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146538586?lang=zh_tw&edition=fundamental","pubTime":"2026-04-21 21:46","pubTimestamp":1776779188,"startTime":"0","endTime":"0","summary":"生物技术巨头Moderna, Inc.宣布，其研发的mRNA联合疫苗Mcombriax已正式获得欧盟委员会的市场营销授权。该疫苗是全球首个采用mRNA技术同时针对流感和COVID-19的联合疫苗，标志着传染病预防领域取得重大突破。\n此次授权为欧盟成员国接种Mcombriax铺平道路，有望简化疫苗接种流程，提升公共卫生防护效率。Moderna的创新疫苗技术平台再次展现其应对复杂病毒威胁的潜力。\n业界分析指出，此次获批将强化Moderna在欧洲疫苗市场的竞争地位，并为其他多价疫苗研发提供重要参考。随着秋冬呼吸道疾病高发季临近，联合疫苗的市场需求预计将持续增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNX","BK4534","MRNA","MRNY","BK4501","BK4533","BK4532","BK4585","BK4588","BK4568","BK4139","BK4551","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165220276","title":"OpenAI攜手安進、Moderna等業界巨頭 全面部署Gpt-Rosalind人工智能工作流解決方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1165220276","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165220276?lang=zh_tw&edition=fundamental","pubTime":"2026-04-17 03:00","pubTimestamp":1776366021,"startTime":"0","endTime":"0","summary":"人工智能领军企业OpenAI近日宣布，正与多家行业领先机构展开深度合作，将突破性语言模型Gpt-Rosalind整合至其核心工作流程中。参与此次技术落地的合作伙伴包括生物技术巨头安进、疫苗先驱Moderna、非营利科研机构艾伦研究所以及科学服务领域领导者赛默飞世尔等知名组织。此次合作标志着Gpt-Rosalind技术在生命科学和医疗研究领域的规模化应用迈出关键一步。从制药企业的靶点发现到科研机构的数据挖掘，Gpt-Rosalind正在不同场景下验证其变革传统工作模式的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0266013472.USD","LU1623119135.USD","LU1670628061.USD","IE00B19Z9505.USD","LU0122379950.USD","LU0342679015.USD","BK4139","BK4566","BK4568","LU0316494557.USD","TMO","IE0002141913.USD","BK4551","IE00BQXX3F31.USD","IE00B2B36J28.USD","LU0640476718.USD","IE00B19Z8X17.USD","BK4581","LU2357305700.SGD","BK4535","LU2764263203.CNY","LU1983299246.USD","LU2063271972.USD","LU1803068623.USD","LU1061106388.HKD","LU2264538146.SGD","LU1153585028.USD","LU0234572021.USD","LU2125909759.SGD","LU1923621640.USD","LU1670627923.USD","LU0882574055.USD","LU1057294990.SGD","BK4599","LU1291159041.SGD","LU1720051108.HKD","LU0320765489.SGD","LU2764262908.HKD","LU0889565916.HKD","LU2089984988.USD","IE0009355771.USD","LU2112291526.USD","LU0957791311.USD","LU0058720904.USD","BK4532","LU1989771016.USD","LU1791710400.SGD","LU2092937221.SGD","MRNY","LU0011850046.USD","LU2211815571.USD","LU0070302665.USD","BK4548","LU0320765992.SGD","GB00BDT5M118.USD","LU2298321311.HKD","LU0345770993.USD","IE00BJT1NW94.SGD","LU2360108059.USD","LU2433249047.HKD","BK4588","LU2242652126.USD","LU1923622291.USD","LU0345770308.USD","LU2242646821.SGD","BK4121","LU1854104046.USD","LU0208291251.USD","LU0289739699.SGD","LU2125910179.SGD","MRNX","IE0034235188.USD","LU1988902786.USD","LU2211814178.USD","SG9999001440.SGD","AMGN","IE00BQXX3D17.EUR","LU1571399168.USD","LU2041044095.USD","LU2125909593.SGD","BK4534","LU1280957306.USD","BK4585","LU1791710582.SGD","MRNA","LU0557290698.USD","IE00B4R5TH58.HKD","LU0528227936.USD","LU1854103824.USD","BK4501","IE00B19Z8W00.USD","LU2543165471.USD","LU0109394709.USD","LU1923622614.USD","LU1815333072.USD","IE00B1BXHZ80.USD","LU0114720955.EUR","LU2764263039.SGD","LU2720916845.USD","IE00BFTCPJ56.SGD","LU1064131342.USD","LU0061474960.USD","LU0868494617.USD","LU2125909916.SGD","IE00BQXX3C00.GBP","LU1712237335.SGD","LU2125910336.SGD","LU2468319806.SGD","LU0823416689.USD","LU2125909247.SGD","LU1023059063.AUD","IE00BJJMRZ35.SGD","LU1548497426.USD","LU0096362180.USD","LU1633808545.USD","LU1720051017.SGD","BK4533","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199935387","title":"Moderna將於2026年7月8日前向Arbutus/Genevant支付9.5億美元無條件一次性款項","url":"https://stock-news.laohu8.com/highlight/detail?id=1199935387","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199935387?lang=zh_tw&edition=fundamental","pubTime":"2026-03-05 19:10","pubTimestamp":1772709057,"startTime":"0","endTime":"0","summary":"生物技术巨头Moderna, Inc.宣布，其已承诺在2026年7月8日或之前，向合作方Arbutus Biopharma及其子公司Genevant Sciences支付一笔总额高达9.5亿美元的无条件一次性款项。此次支付不附带任何后续条件，标志着双方在相关技术平台合作上的一个重要财务里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNY","BK4585","BK4551","BK4588","BK4139","BK4532","BK4548","MRNA","BK4534","BK4501","MRNX","BK4533","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144697251","title":"ETF日報｜三倍做多半導體ETF漲近6%；納指三倍做多ETF升逾4%；加密與半導體產品相對跑贏","url":"https://stock-news.laohu8.com/highlight/detail?id=1144697251","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144697251?lang=zh_tw&edition=fundamental","pubTime":"2026-03-05 09:12","pubTimestamp":1772673133,"startTime":"0","endTime":"0","summary":"美股ETF涨幅Top5$2倍做多GEMI ETF-Leverage Shares$上涨65.93%。该产品两倍做多Galaxy Digital，因公司股价上涨，杠杆效应放大当日涨幅。大盘指数ETF涨幅Top 5$纳指三倍做多ETF$上涨4.49%。$三倍做多MSCI新兴市场ETF-Direxion$上涨2.92%。该产品三倍做多美国小盘股指数，指数当日上行使杠杆产品录得涨幅。该产品三倍做多半导体板块，芯片股集体走强推动杠杆产品上行。该产品配置不动产优先股，相关资产价格上行推动产品上涨。","market":"us","thumbnail":"https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CONI","BK4550","FAS","XLY","BK4551","BK4585","UCO","LU1861220207.SGD","LU2360107671.USD","EWP","AGQ","GEMG","GLXY","MRNX","TNA","USO","NBIZ","BK4516","BK4596","CWB","NBIS","BK4595","ASTN","BK4535","COIN","PFFR","BKLN","SMST","BK4112","QLD","BK4554","LU1861559042.SGD","IREZ","ICVT","SOXL","UGL","PXIU","GLXU","SRLN","MRNA","BK4588","EDC","LU1861217088.USD","LU1861558580.USD","GLGG","BK4539","MSTR","DGP","IREN","TQQQ","UPXI","GEMI","BK4600","IYZ","SMH","ASTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132841899","title":"Moderna股價盤前飆升3.7% 公司同意支付高達22.5億美元和解新冠疫苗專利糾紛","url":"https://stock-news.laohu8.com/highlight/detail?id=1132841899","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132841899?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 17:10","pubTimestamp":1772615446,"startTime":"0","endTime":"0","summary":"Moderna, Inc. (MRNA) 股价在盘前交易中强势上涨3.7%，此前该公司宣布已达成协议，将支付最高22.5亿美元，以了结与其新冠疫苗相关的专利纠纷。这一重大和解协议消除了笼罩在该公司头顶的一大不确定性，为市场注入了积极情绪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNY","MRNX","BK4548","BK4551","BK4139","BK4585","MRNA","BK4532","BK4501","BK4534","BK4568","BK4588","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136696285","title":"Moderna預計2026年恢復營收增長，年末流動性超50億美元，2028年實現盈虧平衡","url":"https://stock-news.laohu8.com/highlight/detail?id=1136696285","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136696285?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 05:21","pubTimestamp":1772572873,"startTime":"0","endTime":"0","summary":"Moderna公司宣布，预计在2026年将重返营收增长轨道，并在该财年结束时保持超过50亿美元的流动性储备。这一战略规划旨在推动公司在2028年实现盈亏平衡目标。\n根据最新披露的财务展望，这家生物技术巨头正通过优化现金流管理和业务拓展双轮驱动，为后疫情时代的可持续发展奠定基础。其资金储备将有效支持mRNA技术平台的创新研发与商业化布局。\n公司强调，这一系列财务目标体现了其对长期价值创造的承诺，同时为应对市场波动提供了充足缓冲空间。随着疫苗业务进入稳定期，非新冠管线的进展将成为未来营收增长的关键驱动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNY","BK4585","BK4551","BK4588","BK4139","BK4532","BK4548","MRNA","BK4534","BK4501","MRNX","BK4533","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173155904","title":"Roivant Sciences子公司Genevant將向Moderna授予傳染病應用LNP遞送技術非獨家許可","url":"https://stock-news.laohu8.com/highlight/detail?id=1173155904","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173155904?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 05:21","pubTimestamp":1772572870,"startTime":"0","endTime":"0","summary":"根据和解协议，Roivant Sciences Ltd.旗下子公司Genevant Sciences将向Moderna, Inc.授予一项非独家许可，允许其将脂质纳米颗粒递送技术用于传染病领域的应用。此项安排解决了双方之间存在的知识产权争议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNX","ABUS","BK4501","BK4568","BK4548","BK4534","ROIV","BK4585","BK4139","BK4532","BK4551","BK4588","MRNA","BK4533","MRNY","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143945821","title":"Moderna預計2026年第一季度將因和解支付計入9.5億美元費用","url":"https://stock-news.laohu8.com/highlight/detail?id=1143945821","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143945821?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 05:19","pubTimestamp":1772572752,"startTime":"0","endTime":"0","summary":"生物技术巨头Moderna近日披露，公司预计在2026年第一季度财务报表中确认一笔高达9.5亿美元的费用。这笔巨额支出与一项重大和解协议的支付义务直接相关，反映出公司在法律及商业纠纷解决方面面临的财务影响。该费用的确认将遵循美国通用会计准则（GAAP）的要求，并对当期利润产生显著影响。分析人士指出，此次预提费用虽可能短期压制股价，但彻底解决历史遗留问题有助于Moderna更专注于mRNA技术管线的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4548","BK4588","MRNY","BK4501","BK4533","MRNA","BK4551","BK4585","BK4139","BK4568","MRNX","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140512903","title":"Moderna最新預測：2026年末現金及現金等價物預計達45-50億美元區間","url":"https://stock-news.laohu8.com/highlight/detail?id=1140512903","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140512903?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 05:19","pubTimestamp":1772572752,"startTime":"0","endTime":"0","summary":"Moderna, Inc. (MRNA) 最新更新了其财务展望，宣布将2026年末的现金及现金等价物预期调整至45亿至50亿美元的范围。这一修正后的预测反映了公司对其未来现金流状况的重新评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4501","BK4533","BK4532","BK4548","BK4588","MRNX","BK4568","BK4551","BK4585","MRNY","BK4139","BK4534","MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192639525","title":"Moderna宣佈新冠流感聯合疫苗Mcombriax或於2026/2027季登陸部分歐盟市場","url":"https://stock-news.laohu8.com/highlight/detail?id=1192639525","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192639525?lang=zh_tw&edition=fundamental","pubTime":"2026-02-27 22:27","pubTimestamp":1772202434,"startTime":"0","endTime":"0","summary":"生物技术公司Moderna近日发布声明称，其研发的新冠与流感联合疫苗Mcombriax有望在2026至2027年流感季期间于部分欧盟国家上市。这一突破性疫苗将两种重要呼吸道病毒的防护合二为一，若获批将成为全球首个针对新冠和流感的联合疫苗。该公司表示，目前正与欧洲药品管理局等监管机构密切沟通，加速推进疫苗的审批流程。市场分析指出，此类组合疫苗若成功面世，不仅可简化接种程序，还能显著提升公共卫生防控效率。随着秋冬呼吸道疾病高发季的常态化，多联疫苗的开发已成为全球医药企业的重点攻关方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNY","BK4532","BK4139","BK4551","BK4533","MRNX","BK4501","BK4585","BK4588","MRNA","BK4568","BK4548","BK4534"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":57,"code":"91000000","status":"200"}]}}